Drugs / Tumor Purged/CD25 Depleted Lymphocytes
Tumor Purged/CD25 Depleted Lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00923351 | Jun 2007 → Aug 2012 | alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, neuroblastoma, peripheral primitive neuroectodermal tumor | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor Purged/CD25 Depleted Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923351 ↗ |
| Modality | Cell therapy | “Infusion of 8H9/CD25 depleted autologous lymphocyte infusion” NCT00923351 ↗ |
| Route | Intravenous | “Patients' white cells are returned to them by infusion through a vein” NCT00923351 ↗ |